Table 1.
Pre-treatment patient characteristics
| Category | Number | Percentage | |
|---|---|---|---|
| Age (mean ± SD) | 49.4 ± 10.7 years | ||
| Pretreatment size (mean ± SD) | 5.6 ± 2.8 cm | ||
| Chemotherapy regimen | |||
| Dose dense AC-T | 50 | 48.6 | |
| AC-T | 18 | 17.5 | |
| FEC-D | 29 | 28.2 | |
| ED | 1 | 1.0 | |
| TC | 4 | 3.9 | |
| Estrogen Receptor Status | |||
| Positive | 66 | 64.1 | |
| Negative | 37 | 35.9 | |
| Progesterone receptor status | |||
| Positive | 58 | 56.3 | |
| Negative | 45 | 43.7 | |
| HER2 receptor status | |||
| Positive | 32 | 31.1 | |
| Negative | 71 | 68.9 | |
| Classification | |||
| Luminal A | 30 | 29.1 | |
| Luminal B (HER2-negative) | 17 | 16.5 | |
| Luminal B (HER2-positive) | 18 | 17.5 | |
| HER2 positive | 13 | 12.6 | |
| Triple-negative | 24 | 23.3 | |
| Laterality | |||
| Left | 47 | 45.6 | |
| Right | 55 | 35.4 | |
| Bilateral | 1 | 1.0 | |
| Menopausal status | |||
| Pre-menopausal | 57 | 55.3 | |
| Post-menopausal | 37 | 35.9 | |
| Peri-menopausal | 7 | 6.8 | |
| Not available | 2 | 1.9 | |
| Histology | |||
| IDC | 97 | 94.2 | |
| ILC | 3 | 2.9 | |
| IMC | 1 | 1.0 | |
| Mixed ILC/IDC | 2 | 1.9 | |
| Lymphovascular invasion | |||
| Negative | 50 | 48.5 | |
| Positive | 45 | 43.7 | |
| Not available | 8 | 7.8 | |
| T (tumor) stage | |||
| T1 | 2 | 1.9 | |
| T2 | 44 | 42.7 | |
| T3 | 46 | 44.7 | |
| T4 | 11 | 10.7 | |
| Clinical N (nodal) stage | |||
| N0 | 28 | 27.2 | |
| N1 | 62 | 60.2 | |
| N2 | 12 | 11.7 | |
| N3 | 1 | 1.0 | |
| Stage group | |||
| IIA | 16 | 15.5 | |
| IIB | 37 | 35.9 | |
| IIIA | 38 | 6.9 | |
| IIIB | 11 | 10.7 | |
| IIIC | 1 | 1.0 | |
| Pathologic N (nodal) status | |||
| Negative | 10 | 9.7 | |
| Positive | 80 | 77.7 | |
| N/A | 13 | 12.6 | |
Abbreviations: A doxorucibin (Adriamycin), C cyclophosphamide, D docetaxel, E epirubicin, F 5-fluorouracil, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, IMC invasive mammary carcinoma, SD standard deviation, T paclitaxel (Taxol)